Microneedle technology in the treatment of ocular diseases: Advances and applications

IF 11.9 1区医学 Q1 PHARMACOLOGY & PHARMACY

Asian Journal of Pharmaceutical Sciences Pub Date : 2026-04-01 Epub Date: 2026-01-31 DOI:10.1016/j.ajps.2026.101129

Jing Li, Zi Yan, Dengxuan Mao, Xiumei Liu, Peixin Lee, Yaqi Lyu, Nianping Feng

{"title":"Microneedle technology in the treatment of ocular diseases: Advances and applications","authors":"Jing Li, Zi Yan, Dengxuan Mao, Xiumei Liu, Peixin Lee, Yaqi Lyu, Nianping Feng","doi":"10.1016/j.ajps.2026.101129","DOIUrl":null,"url":null,"abstract":"<div><div>Microneedle (MN) technology has emerged as a transformative approach for treating ocular diseases, addressing the limitations of conventional drug delivery methods such as low bioavailability and poor patient compliance. This review highlights the advancements and applications of MNs in managing both anterior and posterior segment ocular diseases. MNs overcome physiological barriers, enabling precise, minimally invasive drug delivery with enhanced efficacy. Various MN designs, such as solid, coated, soluble, hollow, hydrogel and cryo-MNs, are tailored for specific therapeutic needs, offering rapid or sustained drug release. Applications include treating keratitis, glaucoma, age-related macular degeneration and diabetic retinopathy, demonstrating improved drug penetration and reduced side effects. Despite challenges in manufacturing and clinical translation, MN technology holds promise for revolutionizing ocular therapeutics through innovations in materials, design, and personalized medicine.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 2","pages":"Article 101129"},"PeriodicalIF":11.9000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1818087626000152","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Microneedle (MN) technology has emerged as a transformative approach for treating ocular diseases, addressing the limitations of conventional drug delivery methods such as low bioavailability and poor patient compliance. This review highlights the advancements and applications of MNs in managing both anterior and posterior segment ocular diseases. MNs overcome physiological barriers, enabling precise, minimally invasive drug delivery with enhanced efficacy. Various MN designs, such as solid, coated, soluble, hollow, hydrogel and cryo-MNs, are tailored for specific therapeutic needs, offering rapid or sustained drug release. Applications include treating keratitis, glaucoma, age-related macular degeneration and diabetic retinopathy, demonstrating improved drug penetration and reduced side effects. Despite challenges in manufacturing and clinical translation, MN technology holds promise for revolutionizing ocular therapeutics through innovations in materials, design, and personalized medicine.

Abstract Image

查看原文本刊更多论文

微针技术在眼部疾病治疗中的进展与应用

微针（MN）技术已成为治疗眼部疾病的一种变革性方法，解决了传统给药方法的局限性，如生物利用度低和患者依从性差。本文综述了MNs在治疗前、后段眼病中的进展和应用。MNs克服了生理障碍，能够精确、微创地给药，提高了疗效。各种MN设计，如固体、包被、可溶性、空心、水凝胶和冷冻MN，是为特定的治疗需求量身定制的，提供快速或持续的药物释放。应用包括治疗角膜炎、青光眼、老年性黄斑变性和糖尿病性视网膜病变，显示出改善药物渗透和减少副作用。尽管在制造和临床转化方面存在挑战，但MN技术有望通过材料、设计和个性化医疗的创新来彻底改变眼科治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Journal of Pharmaceutical Sciences Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

18.30

自引率

2.90%

发文量

审稿时长

14 days

期刊介绍： The Asian Journal of Pharmaceutical Sciences (AJPS) serves as the official journal of the Asian Federation for Pharmaceutical Sciences (AFPS). Recognized by the Science Citation Index Expanded (SCIE), AJPS offers a platform for the reporting of advancements, production methodologies, technologies, initiatives, and the practical application of scientific knowledge in the field of pharmaceutics. The journal covers a wide range of topics including but not limited to controlled drug release systems, drug targeting, physical pharmacy, pharmacodynamics, pharmacokinetics, pharmacogenomics, biopharmaceutics, drug and prodrug design, pharmaceutical analysis, drug stability, quality control, pharmaceutical engineering, and material sciences.